Skip to main content
 
  • Engineering any genome, at any site, in any way

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech

News

Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells

November 18, 2019
Findings Released Today in Nature Biotechnology BERKELEY, Calif. – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering with Type I CRISPR-Cas...

Caribou Biosciences Announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics

September 26, 2019
BERKELEY, CA – September 26, 2019 –  On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. (Intellia) and Caribou Biosciences, Inc. (Caribou). On October 17, 2018,...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...